Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

This study looks at how well therapeutic drug monitoring — measuring the level of the medication brodalumab in a patient's bloodstream — can predict treatment outcomes in people with chronic plaque psoriasis. Brodalumab is a biologic injection used to treat moderate-to-severe psoriasis, and like all biologics, different people break it down at different rates. Some people may have too little in their system (so it doesn't work) while others may have more than needed. This study aims to understand the relationship between drug levels and treatment response. By understanding optimal drug concentrations, doctors may be able to personalise treatment — increasing the dose for poor responders before switching medications, or reducing frequency for those with very high levels. This research is part of a broader movement towards precision medicine in dermatology. You may be eligible if: - You have a confirmed clinical or histological (biopsy) diagnosis of chronic plaque psoriasis - You are currently being treated with brodalumab at a standard dosing schedule - You are willing and able to sign an informed consent form You may NOT be eligible if: - Your predominant psoriasis type is not plaque psoriasis (e.g., pustular, erythrodermic) - You are pregnant, breastfeeding, or planning a pregnancy - You are unable or unwilling to have multiple blood draws - You are on a non-standard brodalumab dosing schedule Talk to your doctor to see if this trial is right for you.